2014 Financial Results

Solid growth in sales:

• Up 8.7%, including BioFire and at constant exchange rates
• Up 3.8%, at constant exchange rates and scope of consolidation

Contributive operating income before non-recurring items*: €227 million, in line with the objective set at the beginning of the year

Sustained successful sales performance by BioFire and FilmArray® in molecular biology

Significant strategic and operating advances, with the signature of eight business development agreements

Higher contributive operating income before non-recurring items expected in 2015, while the Company continues its efforts in sales & marketing, production and innovation, as well as its priority action plans to sustainably strengthen operating performance

Alexandre Mérieux, Chief Executive Officer, said: "In 2014, bioMérieux reached several structural milestones that were essential to its operating organization and strategy, while enhancing its portfolio of molecular biology and automated clinical microbiology products. In addition, we improved our manufacturing level at the site in Durham, NC. In this demanding environment, our contributive operating income before non-recurring items was in line with the target set early in the year. In 2015, we will pursue our strategy by stepping up FilmArray® deployment and the market launch of our new systems, reinforcing our footprint in the Asia-Pacific region, and strengthening our operating performance – all of which will help to secure our sustainable and profitable growth. We expect our contributive operating income before non-recurring items to improve to between €240 million and €265 million."

MARCY L'ETOILE, FRANCE - March 11, 2015 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met yesterday under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the year ended December 31, 2014.